May 16, 2011
As Adoption Deepens Among Prescribers, Satisfaction with Gilenya Remains Muted Due to Continuing Issues with Novartis Support, Managed Care Coverage, and Safety Perceptions, According to a Recent Report from BioTrends
- /
- /
- /
May 16, 2011 EXTON, Penn.–(BUSINESS WIRE)–At six months post launch, market share of Novartis’ Gilenya, the newest disease-modifying agent (DMA)…
